A phase III, Prospective, Double-Blind, Randomized, Placebo-Controlled Trial of Throbolysis in imaging-eligible, late-window patients to assess the efficacy and safety of tenecteplase
This study enrolls adults who have had a recent stroke or stroke symptoms. The purpose of this study is to compare how well the study drug (tenecteplase) works for people with stroke symptoms.
You will be in this study for about 3 months and complete two 90-minute visits during that time. You will be randomized (like flipping a coin) to take either the study drug (tenecteplase) or a placebo. A placebo looks like the study drug but has no active ingredients. You will also have the current standard of care for stroke. Study takes place at Buffalo General, Gates Vascular Institute, and UBMD Neurology locations.
The primary analysis is to compare the efficacy of tenecteplase versus placebo in all patients at Day 90.
-Adults ages 18+.
-Have been diagnosed with a stroke or stroke symptoms.
-Please contact the research team for other eligibility criteria.
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the
contact information above or email firstname.lastname@example.org and someone will assist you.
Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality
assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided
in the aforementioned ways, please contact email@example.com.